Case Reports in Gastrointestinal Medicine

Case Reports in Gastrointestinal Medicine / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 3607101 |

Monjur Ahmed, "Simultaneous Occurrence of Colonic Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (MALToma) and Lung Cancer", Case Reports in Gastrointestinal Medicine, vol. 2018, Article ID 3607101, 3 pages, 2018.

Simultaneous Occurrence of Colonic Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (MALToma) and Lung Cancer

Academic Editor: Yoshifumi Nakayama
Received31 Aug 2018
Revised24 Oct 2018
Accepted11 Nov 2018
Published09 Dec 2018


Colonic MALToma accounts for 2.5% of all MALTomas. MALToma can be associated with certain chronic infections, autoimmune disorders, Waldenstrom’s macroglobulinemia, and old age. Synchronous MALTomas can occur in multiple organs. Simultaneous occurrence of colonic MALToma and colon cancer has been reported. A case of colonic MALToma and lung cancer is described here.

1. Introduction

Colonic MALToma is rare in our clinical practice. Although colonic MALToma can be completely asymptomatic, patients may present with different symptoms when the size of MALToma increases. Many cases of colonic MALToma are diagnosed as an incidental finding. Associated malignancy like lung cancer has never been reported.

2. Case

An 83-year-old white male presented with melena 3 to 4 times per day and occasional hematochezia over one week. He was known to have atrial fibrillation for which he was on warfarin at home. His INR was supratherapeutic (4.9) few weeks ago at his primary care physician’s office. He was told to hold his warfarin for 2 days and then restart at a lower dose.

Recheck of INR was 2.9 after few days. But he started having melena. His other medical problems included significant cardiac history of coronary artery disease, status post coronary artery bypass graft x 3 in 1980, coronary angioplasty and stent placement in 2004, hypertension, hyperlipidemia, and prostate cancer, status post prostatectomy. He was a social drinker and a smoker. He was active in his daily life. His family history was not significant. His home medications were warfarin, sotalol, valsartan, atorvastatin, ezetimibe, isosorbide mononitrate, folic acid, cholecalciferol, ascorbic acid, and selenium.

Examination showed pulse 62/minute, blood pressure 118/67 mm Hg, pale conjunctiva, and abdomen that was soft, nontender, and with no palpable mass. Rectal examination revealed melanotic occult blood positive stool. The remainder of the examination was unremarkable. Laboratory studies showed hemoglobin 7 gm/dl, white cell count 11,400/cmm, and platelet count 156,000/cmm. Patient was started on intravenous pantoprazole. EGD showed mild bulbar duodenitis and a small superficial ulcer and multiple nonbleeding angioectasias in the gastric antrum. The angioectasias were ablated by argon plasma coagulation. Antral biopsy was negative for H. pylori infection. Colonoscopy showed moderate sigmoid diverticulosis, 1.5 cm pedunculated sigmoid colon polyp which was snared and retrieved. There was a subcentimeter nodular area with abnormal vascular pattern in the transverse colon (Figure 1).

Polyp histology came back as tubular adenoma and the nodular area showed marked small lymphocytic infiltrate predominantly comprised of B-cells with lymphoepithelial lesion (Figure 2). The B cells were negative for CD5, CD10, BCL-1, and BCL-6. CD 21 highlighted expanded and disrupted follicular dendritic meshwork. Concurrent molecular studies detected a clonal immunoglobulin heavy chain (IGH) rearrangement. These findings were consistent with extranodal marginal zone lymphoma or colonic MALToma.

PET/CT scan showed a 3.9 × 3.0 cm ground glass opacity in the upper lobe of right lung (Figures 3 and 4), which had increased in size since the prior CT done 8 years ago when it was measured 1.9 × 1.1 cm (Figure 5). The lesion was suggestive of low-grade adenocarcinoma of the lung as it did not have any hypermetabolic activity. There was no focal hypermetabolic activity in the liver or abdomen. The patient refused to have any biopsy of the lung mass. He was seen by an oncologist for further management. He did not want to have any surgery or chemotherapy for his lung cancer. The patient was recommended to have another colonoscopy done in 6 months’ time for follow-up of his colonic MALToma.

3. Discussion

MALToma also known as extranodal marginal zone lymphoma, accounts for 7 to 8% of all cases of B-cell lymphoma [1]. Gastric MALToma is the commonest site. Nongastric sites of MALToma include small intestine, colon, rectum, lung (bronchus-associated lymphoid tissue), salivary gland, thyroid gland, skin, and eye [2].

Patients may remain completely asymptomatic or may present with various symptoms like gastrointestinal bleeding, abdominal pain, diarrhea, fever, night sweats, anorexia, weight loss, and anemia [3]. Colonoscopically we may find a polypoid lesion, mass lesion, elevated lesion, ulcerative lesion, flat lesion, erythema with ecstatic blood vessels, and thickening of mucosal folds [46]. Histologically, as per the World Health Organization, MALToma is characterized by a lymphocytic infiltrate in the marginal zone of lymphoid follicle and interfollicular region. The infiltrate is composed of morphologically heterogeneous small B cells, which include marginal zone cells, small lymphocytes, cells resembling monocytes, scattered immunoblasts, and centroblast-like cells [7]. Another typical finding of MALToma is the lymphoepithelial lesion characterized by invasion and disruption of adjacent glandular epithelium by the neoplastic cells with morphological changes within epithelial cells [8].

The monoclonality of a particular MALToma can be confirmed by monoclonal IGH gene rearrangement in molecular study [9]. The treatment of colonic MALToma is not yet standardized. At the present time, surgery and chemotherapy are the main lines of treatment. Single agent chemotherapy with Rituximab was found to be successful in a case series [10]. An asymptomatic small sized colonic MALToma can be managed conservatively with periodic follow-up [3].

There are some predisposing factors for the development of MALToma. These include chronic infection like H. pylori-induced chronic gastritis (gastric MALToma), Borrelia burgdorferi infection (cutaneous MALToma), Chlamydia psittaci infection (lacrimal gland MALToma), autoimmune disorders like Sjogren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, (Hashimoto’s thyroiditis, relapsing polychondritis, and Wegener’s granulomatosis [11, 12]. MALToma can also be associated with old age, weak immune system, and Waldenstrom’s macroglobulinemia [13]. Synchronous MALToma of colon and adenocarcinoma of colon and synchronous MALToma of colon and stomach as well as synchronous MALToma of colon, stomach, and lung have been reported in the literature [1416].

The lung mass seen in our case has differential diagnoses of lung cancer vs. MALToma. But lack of hypermetabolic activity on PET scan suggested lung cancer. The case we described is unique in finding the simultaneous occurrence of colonic MALToma and low-grade lung cancer (suspected) suggesting that another malignancy should be looked for if no predisposing factor for MALToma is obvious.

Conflicts of Interest

The author declares that they have no conflicts of interest.


  1. S. M. Cohen, M. Petryk, M. Varma, P. S. Kozuch, E. D. Ames, and M. L. Grossbard, “Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue,” The Oncologist, vol. 11, no. 10, pp. 1100–1117, 2006. View at: Publisher Site | Google Scholar
  2. S. Sallach, T. Schmidt, C. Pehl et al., “Primary low-grade B cell non-Hodgkin's lymphoma of MALT type simultaneously arising in the colon and in the lung report of a case,” Diseases of the Colon & Rectum, vol. 44, no. 3, pp. 448–452, 2001. View at: Publisher Site | Google Scholar
  3. M. Chan, A. Rostom, C. Faught, and C. Dube, “A262 colonic mucosa-associated lymphoid tissue (malt) lymphoma, a rare occurence: a literature review and case series,” Journal of the Canadian Association of Gastroenterology, vol. 1, no. suppl_2, pp. 376-377, 2018. View at: Publisher Site | Google Scholar
  4. R. Akasaka, T. Chiba, A. K. Dutta et al., “Colonic Mucosa-Associated Lymphoid Tissue Lymphoma,” Case Reports in Gastroenterology, vol. 6, no. 2, pp. 569–575, 2012. View at: Publisher Site | Google Scholar
  5. N. Hasegawa, K. Kato, K. Yamada et al., “Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) of the sigmoid colon,” Gastrointestinal Endoscopy, vol. 52, no. 6, pp. 802–804, 2000. View at: Publisher Site | Google Scholar
  6. R. Piotrowski, R. Kramer, and A. Kamal, “Extranodal Marginal Zone B-Cell (Mucosa-Associated Lymphoid Tissue) Lymphoma of the Colon Presenting as an Obstructing Mass,” Clinical Gastroenterology and Hepatology, vol. 6, no. 4, pp. e18–e19, 2008. View at: Publisher Site | Google Scholar
  7. E. S. Jaffe, N. L. Harris, H. Stein, and J. W. Vardiman, World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon, France, 2008.
  8. P. G. Isaacson, A. C. Wotherspoon, T. Diss, and L. X. Pan, “Follicular colonization in B-cell lymphoma of mucosa-associated lymphoid tissue,” The American Journal of Surgical Pathology, vol. 15, no. 9, pp. 819–828, 1991. View at: Publisher Site | Google Scholar
  9. S. Konoplev, P. Lin, X. Qiu, L. J. Medeiros, and C. C. Yin, “Clonal relationship of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue involving different sites,” American Journal of Clinical Pathology, vol. 134, no. 1, pp. 112–118, 2010. View at: Publisher Site | Google Scholar
  10. M. Raderer, G. Jäger, S. Brugger et al., “Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma,” Oncology, vol. 65, no. 4, pp. 306–310, 2003. View at: Publisher Site | Google Scholar
  11. A. Ambrosetti, R. Zanotti, C. Pattaro et al., “Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection,” British Journal of Haematology, vol. 126, no. 1, pp. 43–49, 2004. View at: Publisher Site | Google Scholar
  12. B. Kiesewetter, M. Troch, L. Müllauer, and M. Raderer, “Running in the family: MALT lymphoma and autoimmune disease in mother and daughter,” World Journal of Gastrointestinal Oncology, vol. 4, no. 2, pp. 26–29, 2012. View at: Google Scholar
  13. P. Lin, T. J. Molina, J. R. Cook, and S. H. Swerdlow, “Lymphoplasmacytic Lymphoma and Other Non–Marginal Zone Lymphomas With Plasmacytic Differentiation,” American Journal of Clinical Pathology, vol. 136, no. 2, pp. 195–210, 2011. View at: Publisher Site | Google Scholar
  14. P. Devi, L. Pattanayak, and S. Samantaray, “Synchronous adenocarcinoma and mucosa-associated lymphoid tissue lymphoma of the colon,” Saudi Journal of Gastroenterology, vol. 17, no. 1, pp. 10–4103, 2011. View at: Google Scholar
  15. K. Singh, S. Gandhi, and B. Doratotaj, “Synchronous MALT lymphoma of the colon and stomach and regression after eradication of Strongyloides stercoralis and Helicobacter pylori,” BMJ Case Reports, 2018. View at: Publisher Site | Google Scholar
  16. M. D. Fares, O. M. Abbas, and G. W. Jamaleddine, “Extranodal marginal zone lymphoma of MALT involving the lungs, the stomach, and the colon,” Lung Cancer, vol. 54, no. 3, pp. 427–429, 2006. View at: Publisher Site | Google Scholar

Copyright © 2018 Monjur Ahmed. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.